Peptide LexiconAll compounds

Pasireotide (Signifor): The Six-Amino-Acid Ring That Mimics Somatostatin — What It Is, What Its Trials in Cushing's Disease and Acromegaly Showed, and the Blood-Sugar Problem

Pasireotide is a cyclohexapeptide somatostatin analogue sold as Signifor (twice-daily injection, Cushing's disease) and Signifor LAR (monthly injection, acromegaly and Cushing's disease). Its labels report modest response rates in Cushing's disease, better hormone control than a comparator analogue in acromegaly, and high blood sugar as one of its most common effects.

FDA-approvedSomatostatin analogueTwo forms: twice-daily and monthly

Caroline S · Published 2026-11-20

Length

Cyclohexapeptide (six amino acids in a ring); C58H66N10O9, molecular weight 1,047.2 (PubChem CID 9941444)

Sequence

Ring of six residues per the label's chemical name, carrying 4-aminobutyl (lysine), benzyl, 4-benzyloxybenzyl, indolylmethyl (tryptophan) and phenyl side chains, with a 2-aminoethyl carbamate group

Origin

Synthetic. Signifor, NDA 200677 (original approval 2012-12-14); Signifor LAR, NDA 203255 (2014-12-15); both Recordati Rare Diseases (Drugs@FDA)

Last reviewed

2026-11-20

What is it good for?

Lowering hormone excess from pituitary tumours. Signifor, injected under the skin twice a day, is approved for adults with Cushing's disease when pituitary surgery is not an option or has not cured it. Signifor LAR, a monthly muscle injection, is approved for that and for acromegaly when surgery has not worked or is not an option.

Illustration: A small glass vial of pale amber liquid with a deep green cap on a white surface, a copper light arc behind it.
Illustration

What it is

Pasireotide is a ring of six amino acids built to act like somatostatin, the body's own "switch-off" hormone for growth hormone, insulin and several other secretions. The Signifor label calls it "an injectable cyclohexapeptide somatostatin analogue". Natural somatostatin is a 14-amino-acid hormone, covered in the library's somatostatin entry. Pasireotide is one of three shorter, longer-lasting analogues in clinical use, alongside octreotide and lanreotide.

Property Value Source
Structure Cyclohexapeptide (six-residue ring) Signifor label sections 11, 12.1
Formula C58H66N10O9 PubChem CID 9941444
Molecular weight 1,047.2 PubChem
Salt forms Diaspartate (Signifor); pamoate (Signifor LAR) Labels, section 11
Routes Subcutaneous twice daily; intramuscular every 4 weeks Labels, section 2

How it acts. Somatostatin works through five receptor subtypes, SSTR1 to SSTR5. In the label's laboratory binding table pasireotide's strongest affinity is at SSTR5 (IC50 0.16 nmol/L, against 0.29 for natural somatostatin), followed by SSTR2 (1.0), SSTR3 (1.5) and SSTR1 (9.3), with almost none at SSTR4 (above 100). The Signifor label states that corticotroph tumour cells — the pituitary cells that over-produce ACTH in Cushing's disease — "frequently over-express SSTR5", and that pasireotide "binds and activates the SSTRs resulting in inhibition of ACTH secretion, which leads to decreased cortisol secretion". Lower ACTH means less cortisol from the adrenal glands (the library's ACTH entry explains the chain). In acromegaly, the target is growth hormone and the IGF-1 it drives.

What the trials showed

Cushing's disease (Signifor, twice daily). A phase III multicentre trial randomised 162 patients — 78% women, mean age 40, 83% with disease that persisted or returned after pituitary surgery — to 0.6 mg or 0.9 mg twice daily for six months, then six months open-label. Median baseline urinary free cortisol was 565 nmol/24 h against a normal range of 30–145.

End point at month 6 0.6 mg twice daily 0.9 mg twice daily
Normal 24-h urinary free cortisol, no dose increase (primary) 15% 26%
Normal or ≥50% reduction 34% 41%

The label adds that "dose increases appeared to have minimal effect" on urinary cortisol, and about two-thirds of patients completed six months. There was no placebo arm: the trial compared two doses.

Acromegaly (Signifor LAR, monthly). In 358 drug-naïve patients randomised 1:1 to Signifor LAR 40 mg or another somatostatin analogue (the label does not name it), 31.3% v 19.2% reached mean growth hormone below 2.5 mcg/L with a normal age- and sex-adjusted IGF-1 at month 12. The label notes that the comparator's maximum US dose was not used, because the trial ran in countries where that dose was not approved — a limit on how far the comparison can be read.

What is not established: a placebo-controlled effect size in Cushing's disease, and any use outside the labelled pituitary conditions.

Risks the labels list

  • Most common (20% or more, Signifor): diarrhoea, nausea, hyperglycaemia, gallstones, headache, abdominal pain, fatigue and diabetes mellitus. Signifor LAR's list is similar (diarrhoea, gallstones, hyperglycaemia).
  • Blood sugar: both labels require fasting plasma glucose and HbA1c before treatment; Signifor LAR's warnings name ketoacidosis as well as hyperglycaemia and diabetes.
  • Before the first dose (Signifor): liver tests, ECG, gallbladder ultrasound, potassium and magnesium.
  • Other warnings: low cortisol, slow heart rate and QT prolongation, liver-test elevations, deficiency of other pituitary hormones, and malabsorption of dietary fat.
  • Liver impairment: Signifor starts at 0.3 mg twice daily, maximum 0.6 mg, in moderate (Child-Pugh B) impairment.

Where it stands

Both forms are US prescription drugs held by Recordati Rare Diseases: Signifor, NDA 200677, original approval 14 December 2012, and Signifor LAR, NDA 203255, original approval 15 December 2014 (Drugs@FDA, read 2026-11-20). The current Signifor label is effective 17 February 2026 and the Signifor LAR label 16 July 2024.

Sources opened 2026-11-20: Signifor label (openFDA, effective 2026-02-17: sections 1, 2, 6, 11, 12.1, 14); Signifor LAR label (openFDA, effective 2024-07-16: sections 1, 2, 6, 11, 12.1, 14.1); Drugs@FDA records for NDA 200677 and NDA 203255; PubChem CID 9941444; PubMed E-utilities and ClinicalTrials.gov API v2 counts.

What the research shows

Normalises urinary cortisol in a minority of people with Cushing's disease

Phase III randomised trial of two doses, 162 patients, 6 months: 15% (0.6 mg twice daily) and 26% (0.9 mg twice daily) met the primary end point (Signifor label section 14)

Controls growth hormone and IGF-1 in drug-naïve acromegaly more often than a comparator analogue

Randomised double-blind trial, 358 patients, 12 months: 31.3% v 19.2% reached GH < 2.5 mcg/L with normal IGF-1 (Signifor LAR label section 14.1)

Binds several somatostatin receptor subtypes

Label section 12.1 and its Table 2 (laboratory binding affinities): strongest at SSTR5 (IC50 0.16 nmol/L), weak at SSTR4 (>100 nmol/L); corticotroph tumour cells in Cushing's disease frequently over-express SSTR5

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

United States

Prescription drugs: Signifor (NDA 200677, approved 2012-12-14) and Signifor LAR (NDA 203255, approved 2014-12-15), Recordati Rare Diseases; both listed as prescription in Drugs@FDA (read 2026-11-20).

How it is given

Signifor: 0.6 mg or 0.9 mg under the skin twice daily to start, range 0.3–0.9 mg twice daily. Signifor LAR: intramuscular every 4 weeks by a health professional, starting at 40 mg in acromegaly and 10 mg in Cushing's disease (labels, section 2).

Published record

PubMed: 872 records for 'pasireotide'; ClinicalTrials.gov: 87 studies (2026-11-20).

Frequently asked questions

What is pasireotide?

A synthetic ring of six amino acids that mimics the hormone somatostatin. It is sold as Signifor, a twice-daily injection under the skin, and Signifor LAR, a monthly long-acting injection into muscle, for Cushing's disease and acromegaly.

How is pasireotide different from octreotide and lanreotide?

All three are somatostatin analogues. The Signifor label's laboratory binding table shows pasireotide binding SSTR5 strongly (IC50 0.16 nmol/L, against 0.29 for natural somatostatin) and SSTR1–3 more weakly, with almost no binding at SSTR4 (above 100 nmol/L). It also states that the tumour cells behind Cushing's disease frequently over-express SSTR5.

How well does pasireotide work in Cushing's disease?

In its phase III trial of 162 patients, 15% on 0.6 mg and 26% on 0.9 mg twice daily had normal urinary cortisol at six months without a dose increase. With a looser definition of response (normal or at least halved), the figures were 34% and 41%.

What dose does the label state?

For Signifor, 0.6 mg or 0.9 mg twice daily under the skin to start, within a range of 0.3 to 0.9 mg twice daily, adjusted to response and tolerability. For Signifor LAR, 40 mg (acromegaly) or 10 mg (Cushing's disease) by intramuscular injection every four weeks, given by a health professional.

Why does pasireotide raise blood sugar?

The labels list hyperglycaemia and diabetes among the most common adverse reactions and require fasting glucose and HbA1c before starting, with glucose control optimised first in poorly controlled diabetes. This entry reports the label's warning; it does not add a mechanism the labels do not state.

What other risks do the labels list?

Low cortisol (hypocortisolism), slow heart rate and QT prolongation, raised liver tests, gallstones and their complications, deficiency of other pituitary hormones, and fatty stools from poor fat absorption.